Latest Fund Financial Results News

Biotron Limited reported a half-year loss as it completed the acquisition of Sedarex Limited and advanced its Hepatitis B drug candidate BIT-HBV001, backed by a $2.5 million capital raise. The company faces material uncertainty over its going concern status, hinging on securing further funding.

WAM Strategic Value reported a near 50% drop in net profit for FY2025 but maintained its fully franked dividend, supported by an 8.6% portfolio gain that outperformed market downturns.

CD Private Equity Fund II reported a steep decline in net profit for FY25, with earnings per unit plunging 98%, yet continued to deliver solid distributions to unitholders amid a challenging US private equity market.